KCLG Medical is a clinical research organisation dedicated to bridging the gap between cutting-edge medical science and real-world patient outcomes. We design, conduct, and disseminate rigorous clinical research that changes clinical practice.
Understanding which cancers affect the most people guides where research effort is most urgently needed. Our trial portfolio is shaped by this epidemiological reality.
Source: American Cancer Society, 2024
Source: GLOBOCAN / WHO, 2022
From early-phase trials to translational insights, KCLG Medical operates at every stage of the clinical evidence pipeline — ensuring findings reach the patients and clinicians who need them.
We design and conduct Phase I–III trials across oncology, haematology, and metabolic medicine, with pre-specified endpoints and independent oversight.
Our systematic reviews and meta-analyses distil the best available evidence, informing clinical guidelines and shaping prescribing practice across the NHS and beyond.
We collaborate with NHS Trusts, academic institutions, and industry sponsors — providing site management, investigator support, and regulatory expertise.
All trials are prospectively registered, randomised where appropriate, and conducted in full accordance with GCP and MHRA guidelines.
A Phase II randomised controlled trial investigating whether statin co-administration enhances the efficacy of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.
A biomarker-stratified Phase II adaptive platform trial matching patients to targeted agents based on prospectively validated genomic and proteomic profiles.
Evidence-based commentary, trial updates, and clinical briefings for healthcare professionals and informed patients.
A review of the mechanistic rationale and early clinical data supporting statin co-administration in ibrutinib-treated CLL patients.
A plain-language guide covering informed consent, safety monitoring, your rights as a participant, and what happens at each study visit.
An explanation of how pre-specified statistical analysis plans prevent selective reporting and protect the integrity of trial findings.
"Every day that a proven therapy sits in a journal instead of a clinic, a patient who could have benefited doesn't. Our work exists to close that gap — rigorously, ethically, and urgently."— KCLG Medical Research Team
Learn how to discuss clinical trial participation with your consultant, what eligibility criteria mean, and how to access our active studies.
We work with NHS consultants and GPs to identify eligible patients and support site initiation for our ongoing and upcoming trials.
From academic collaborations to industry-sponsored trials, we offer flexible partnership models with full regulatory and operational support.
